Dakota Wealth Management Has $27.16 Million Stock Holdings in Abbott Laboratories $ABT

Dakota Wealth Management lifted its stake in shares of Abbott Laboratories (NYSE:ABT) by 13.8% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 202,797 shares of the healthcare product maker’s stock after purchasing an additional 24,610 shares during the quarter. Dakota Wealth Management’s holdings in Abbott Laboratories were worth $27,163,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently bought and sold shares of the company. Carr Financial Group Corp increased its holdings in Abbott Laboratories by 2.0% in the third quarter. Carr Financial Group Corp now owns 3,880 shares of the healthcare product maker’s stock worth $520,000 after purchasing an additional 76 shares in the last quarter. Tortoise Investment Management LLC increased its holdings in Abbott Laboratories by 10.7% during the 2nd quarter. Tortoise Investment Management LLC now owns 795 shares of the healthcare product maker’s stock worth $108,000 after purchasing an additional 77 shares in the last quarter. Gemmer Asset Management LLC grew its holdings in Abbott Laboratories by 2.9% during the third quarter. Gemmer Asset Management LLC now owns 2,750 shares of the healthcare product maker’s stock worth $368,000 after buying an additional 78 shares in the last quarter. Bridgewater Advisors Inc. increased its stake in Abbott Laboratories by 0.6% in the 2nd quarter. Bridgewater Advisors Inc. now owns 12,555 shares of the healthcare product maker’s stock valued at $1,607,000 after buying an additional 79 shares during the last quarter. Finally, Global Financial Private Client LLC boosted its position in Abbott Laboratories by 3.3% in the third quarter. Global Financial Private Client LLC now owns 2,469 shares of the healthcare product maker’s stock worth $331,000 after purchasing an additional 79 shares during the last quarter. 75.18% of the stock is currently owned by institutional investors.

Insider Transactions at Abbott Laboratories

In other news, Director Daniel J. Starks bought 10,000 shares of the company’s stock in a transaction dated Wednesday, February 4th. The shares were purchased at an average price of $108.73 per share, for a total transaction of $1,087,300.00. Following the completion of the purchase, the director owned 6,738,817 shares in the company, valued at approximately $732,711,572.41. This represents a 0.15% increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 0.46% of the company’s stock.

Key Stories Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Q4 results and forward guidance: Abbott reported Q4 EPS roughly in line with expectations while revenue was slightly below consensus, but management set FY‑2026 EPS guidance (5.55–5.80) that sits above recent analyst forecasts — a catalyst for investor optimism around underlying margin recovery and recurring businesses. Abbott (ABT) Reports Q4 Earnings: What Key Metrics Have to Say
• Positive Sentiment: Dividend support: Abbott declared a quarterly dividend of $0.63 per share (ex‑dividend Apr 15), reinforcing the stock’s income profile and making the shares more attractive to yield-focused investors.
• Positive Sentiment: Analyst backing and price targets: The stock has multiple buy/overweight ratings and a recent median price target near $140, which provides visible upside support versus the current level and can attract momentum buyers. Abbott Laboratories Stock (ABT) Opinions on Exact Sciences Acquisition
• Neutral Sentiment: Acquisition financing and strategic repositioning: Abbott is arranging large debt financing (reported $20B bond sale) to fund the Exact Sciences acquisition — investors see strategic rationale (expands oncology/diagnostics) but are weighing integration execution and incremental leverage. Abbott Laboratories Stock (ABT) Opinions on Exact Sciences Acquisition
• Negative Sentiment: Product‑safety litigation risk: A wrongful‑death lawsuit alleges defects in the FreeStyle Libre 3/3 Plus glucose monitors and links the devices to multiple deaths and injuries; this raises potential regulatory, recall and settlement risk that could pressure sentiment if litigation expands. Wrongful Death Suit Tests Abbott Libre 3 And Exact Sciences Ambitions

Abbott Laboratories Price Performance

Shares of ABT stock opened at $115.14 on Tuesday. The company has a quick ratio of 1.24, a current ratio of 1.70 and a debt-to-equity ratio of 0.23. The business’s fifty day moving average is $118.19 and its 200 day moving average is $125.68. The stock has a market cap of $200.20 billion, a price-to-earnings ratio of 30.95, a PEG ratio of 1.79 and a beta of 0.75. Abbott Laboratories has a twelve month low of $105.27 and a twelve month high of $141.23.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.50. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.94%. The company had revenue of $11.46 billion during the quarter, compared to analysts’ expectations of $11.80 billion. During the same period last year, the company posted $1.34 EPS. Abbott Laboratories’s revenue was up 4.4% on a year-over-year basis. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Research analysts expect that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be given a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 2.2%. The ex-dividend date of this dividend is Wednesday, April 15th. Abbott Laboratories’s payout ratio is currently 67.74%.

Wall Street Analyst Weigh In

Several equities analysts recently commented on ABT shares. BTIG Research dropped their price objective on Abbott Laboratories from $145.00 to $140.00 and set a “buy” rating on the stock in a research note on Tuesday, February 17th. Citigroup dropped their price objective on Abbott Laboratories from $155.00 to $140.00 and set a “buy” rating for the company in a research note on Friday, January 23rd. Evercore cut their price target on shares of Abbott Laboratories from $144.00 to $138.00 and set an “outperform” rating for the company in a research note on Friday, January 23rd. Raymond James Financial reduced their price objective on Abbott Laboratories from $146.00 to $130.00 and set an “outperform” rating on the stock in a research report on Friday, January 23rd. Finally, William Blair raised shares of Abbott Laboratories to a “strong-buy” rating in a report on Thursday, November 20th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat.com, Abbott Laboratories has an average rating of “Moderate Buy” and an average target price of $137.05.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.